Given these observations, it seems that despite a “cause-and-effect” relationship between SS18-SSX and synovial sarcoma, suppression of SS18-SSX alone could accidentally evoke certain oncogenic events (such as FYN activation) that must be monitored closely for achieving effective therapy. Here, SS18 is linked to synovial sarcoma.